Year in Aesthetics — 2026

AbbVie filed four material events in 2026 (April, May, June, July) tied to Botox, Juvéderm, and Allē loyalty adjustments—a clear signal of margin defense. Simultaneously, Evolus (Jeuveau/Newtox) filed three material events around Evolus Rewards, aggressively courting medspas with rebate and loyalty incentives. The message: pricing power is eroding. Independent injectors face a choice—commit to one ecosystem's loyalty program (and accept lower per-unit margins) or risk losing volume to competitors who do. Practices that relied on stable Botox and filler margins must now model loyalty-program economics into their P&Ls and negotiate harder with reps.

• AbbVie's repeated filings signal active pricing/rebate repositioning
• Evolus targets medspas directly, undercutting traditional dermatology channels
• Loyalty programs now table stakes; margin compression is real

The FDA approved Skinvive by Juvéderm for neck wrinkles, Restylane Contour for temple hollowing, and RHA Dynamic Volume for midface augmentation. Each represents a new revenue line, but none is a blockbuster. Neck injectables, temple work, and midface volume are incremental—not transformative—for most practices. The real win: these approvals give practices more reasons to stock multiple filler brands and justify higher inventory costs. For owners, the trade-off is clear: more SKUs, more sales training, more rebate tracking, and modest uplift per patient. Galderma also signaled progress on RelabotulinumtoxinA (a new botulinum toxin), and L'Oréal increased its stake in Galderma to 20%, hinting at long-term competitive pressure on AbbVie's duopoly.

• Skinvive, Restylane Contour, RHA Dynamic Volume expand the menu
• New indications are incremental revenue, not transformative
• Galderma's backing by L'Oréal signals future competitive intensity

Steel Partners made a $16.75-per-share unsolicited bid for InMode, signaling confidence in device demand and consolidation appetite. Cynosure Lutronic launched XERF (monopolar RF) in Europe and expanded U.S. adoption, positioning non-invasive skin tightening as the growth category. Patient demand for non-invasive treatments is accelerating—likely driven by GLP-1 users seeking skin tightening post-weight loss and by younger patients wanting preventive options. For practice owners, this means device ROI is improving, but competition is intensifying. Standalone practices may struggle to justify capital for multiple platforms; group practices and DSOs have an edge.

• InMode M&A activity reflects strong device-market fundamentals
• XERF adoption accelerates; non-invasive skin tightening is the growth vector
• GLP-1 weight loss drives demand for skin tightening and body contouring
• Capital intensity favors scale and consolidation

Medicare announced it will negotiate the price of Botox and 14 other drugs in 2026—a watershed moment. While Medicare reimbursement is a small slice of aesthetic revenue, the precedent is ominous. If Medicare negotiates Botox down, private payers will follow. Independent practices with high Medicare/Medicaid mix face margin pressure; those serving purely cash patients are insulated but must defend pricing against loyalty programs. The regulatory environment is shifting toward price transparency and payer power. Practices should audit their payer mix, stress-test margins under lower reimbursement, and consider whether loyalty-program commitments lock them into unsustainable economics.

• Medicare price negotiation for Botox signals payer power
• Private payers will likely follow Medicare's lead
• Cash-pay practices have more pricing flexibility but face loyalty-program pressure
• Regulatory headwinds favor large, diversified players

Beyond InMode, 2026 saw active M&A interest across aesthetics. AbbVie's repeated pricing moves suggest it is defending against private-equity and strategic buyers eyeing market share. Galderma's L'Oréal backing signals a well-capitalized competitor preparing for scale. For independent practice owners, consolidation is both threat and opportunity. DSOs and roll-ups are acquiring practices at multiples tied to EBITDA and patient loyalty—but only if the practice has defensible margins and recurring revenue. Practices locked into low-margin loyalty programs or facing GLP-1 demand headwinds are less attractive targets. Owners considering exit should focus on margin stability and patient retention metrics.

• InMode bid reflects strong device-market appetite
• AbbVie and Galderma are actively defending/expanding market share
• DSO consolidation accelerates; multiples favor margin stability and recurring revenue
• Independent practices should audit their attractiveness to buyers

GLP-1 weight-loss drugs (Ozempic, Wegovy, etc.) are reshaping aesthetic demand. Patients losing weight rapidly need skin tightening, body contouring, and facial volume restoration—a tailwind for non-invasive devices and fillers. But GLP-1 also suppresses demand for preventive injectables among younger, health-conscious patients who prioritize weight loss over cosmetics. The net effect is mixed: strong demand for corrective/post-weight-loss treatments, softer demand for routine Botox and lip filler. Practices should reposition their marketing toward post-weight-loss body contouring and skin tightening, and prepare for seasonal demand swings tied to GLP-1 prescription cycles.

• GLP-1 drives demand for skin tightening and body contouring
• Preventive injectable demand may soften as patients prioritize weight loss
• Practices should market post-weight-loss treatments aggressively
• Seasonal demand volatility tied to GLP-1 cycles is likely